Drug Trial Radar · NCT03160833
A Study of HMPL-453 in Patients With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Feb 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
33
Actual
Start
May 23, 2017
Primary completion
Dec 31, 2019
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose escalation study consisting of two stages: Dose-escalation stage (stage 1): Patients will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations. After one week of observation, if no safety issues occur, patients can continue multiple dosing of HMPL-453 QD (quaque die) and start on the DLT (Dose Limited Toxicity) assessment cycles. Each cycle consists of 28-days. Patients are required to draw blood samples for PK and safety analysis at specific time points during the treatment; Dose-Expansion Stage (Stage 2): This stage is to further evaluate the safety, tolerability, PD (pharmacodynamics) profile, and preliminary anti-tumor activity of HMPL-453 at the RP2D (recommended phase 2 dose) in approximately 10 patients with advanced solid tumor.
Conditions
- Solid Tumor, Adult
Interventions
HMPL-453Drug
oral administrative
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTs by the NCI CTCAE v4.03Time frame: Cycle 1 (DLT assessment window 28 days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing 307 Hospital
Beijing, Beijing Municipality, China
Cancer center of SYSU
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.